Compare Bristol-Myers Squibb Co (BMY) vs Coinbase Global, Inc. (COIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Coinbase Global, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $63.81 (market cap $129.94B), while Coinbase Global, Inc. trades at $148.61 (market cap $39.20B). The key difference: Bristol-Myers Squibb Co is far larger — about 3.3× Coinbase Global, Inc.'s market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Coinbase Global, Inc. pays none. Which is the better fit depends on your goals.
| BMY | COIN | |
|---|---|---|
Market Cap | $129.94B | $39.20B |
Sector | Health | Technology |
52-Week High | $65.89 | $387.27 |
52-Week Low | $42.60 | $141.09 |
Enterprise Value | $163.92B | $36.85B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
COIN trades at $148.4, down 0.19% with a bearish technical signal. Recent earnings misses and a net loss in Q2 2026 highlight challenges despite revenue growth. The stock faces pressure from a sluggish crypto market, but maintains strong cash flow and a 55% analyst buy rating with a $207.20 price target.
Outlook remains mixed: strong fundamentals like positive EBITDA and cash flow support long-term potential, but near-term risks from earnings volatility and market sentiment weigh on performance. Investors should balance growth prospects against sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →
